论文部分内容阅读
在1983～1987的5年间,世界医药市场总共投放了254种新的化学本体药(NCE)。就这些药物的发明国而论,半数以上是日本和美国公司研究开发的。以前在药物创新领域总是美国领先,但这5年日本已名列榜首。居第三位的是西德,其后三年呈减少趋势。以下名次是意大利、法国、瑞士和英国。这5年,他们研究开发的NCE年平均上市数分别为5.0、4.2、2.8和2.4。不过这些国家还是应该称道。日本的NCE多为简单的“结构模仿”,欧洲国家则多高度创新。例如1987年4月英国公司Wellcome上市的抗病毒药Retrovir(叠氮胸腺嘧啶核苷)就是世界上第一种投放市场的艾滋病治疗药,它
In the five years from 1983 to 1987, a total of 254 new chemical bulk drugs (NCEs) were launched in the world pharmaceutical market. In the case of the inventors of these drugs, more than half were researched and developed by Japanese and U.S. companies. Before the United States in the field of drug innovation is always the leader, but Japan has topped the list for five years. The third highest was West Germany, showing a decreasing trend in the following three years. The following ranking is Italy, France, Switzerland and the United Kingdom. In these five years, the average NCEs they research and develop are 5.0, 4.2, 2.8 and 2.4, respectively. However, these countries should still commend it. Japan’s NCE mostly simple “structural imitation”, while European countries are more highly innovative. For example, in April 1987, the wellcome listed British company Antiviral Retrovir (azidothymidine) was the first AIDS treatment drug marketed in the world. It